<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544711</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0097</org_study_id>
    <nct_id>NCT02544711</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment</brief_title>
  <acronym>MARGIC</acronym>
  <official_title>Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primitive malignant bone tumor or mixt tumor (compounded of soft tissues and bone) is a rare&#xD;
      pathology particularly within the pelvis, the sacrum or the hip (between 25 and 80 new cases&#xD;
      in France per year).&#xD;
&#xD;
      The reference treatment is a surgical &quot;en bloc&quot; resection associated or not to a medical&#xD;
      treatment. This surgery remains highly challenging because of the complex three-dimensional&#xD;
      geometry of the pelvic bone and the proximity of important organs and neurovascular&#xD;
      structures. The local recurrence rate is significantly increased when the resection does not&#xD;
      respect a safe tissues margin (R0 margin).&#xD;
&#xD;
      A new technology has been developed and used in different reference sites the Patient&#xD;
      Specific Instrument (PSI), manufactured by 3D-Side. The PSI allows for a more secure and&#xD;
      reliable surgical gesture, leading to more frequent R0 margins.&#xD;
&#xD;
      The main objective of this study is to compare the efficiency of the PSI for bone tumor&#xD;
      resections within the pelvis with respect to the reference method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICER between the innovation treatment group and the reference treatment group.</measure>
    <time_frame>3 years</time_frame>
    <description>Incremental Cost-Effectiveness Ratio (ICER) as assessed from the healthcare system perspective: Cost/Local prevented recurrence at 3 years postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0, R1 and R2 margin rates</measure>
    <time_frame>Within 3 years after surgery</time_frame>
    <description>R0, R1 and R2 margin rates as observed by histological exam for each surgical treatment, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and nature of adverse events related to surgery for each treatment group</measure>
    <time_frame>Per-operatively and within 3 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life (QOL) of patients treated by PSI (prospective group)</measure>
    <time_frame>0, 6, 12, 18, 24, 30 and 36 months</time_frame>
    <description>Euroqol questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect estimations of means of Quality Adjusted Life Years (QALYs) of patients treated by the reference treatment (retrospective group) extrapolated from QOL of patients treated by PSI (prospective group)</measure>
    <time_frame>3 years</time_frame>
    <description>QALYs measures for this group will be extrapolated from the prospective group by estimating the impact of a local recurrence on health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSTS score</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>Musculoskeletal Tumor Society (MSTS) Score which evaluates 6 items: pain, function, emotional acceptance, walking capacity, technical walking aids, gait.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TESS Score</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>Toronto Extremity Salvage Score (TESS) which evaluates 30 items about the global function and patient's activity level.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Sarcoma, Bone Tumor</condition>
  <arm_group>
    <arm_group_label>Prospective group :Innovation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical treatment using a patient specific instrument (PSI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective group: Reference</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional surgical treatment without PSI, using 2D imaging planification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patient specific instrument</intervention_name>
    <description>The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.</description>
    <arm_group_label>Prospective group :Innovation</arm_group_label>
    <other_name>PSI-T</other_name>
    <other_name>3D-Side</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional surgical treatment</intervention_name>
    <description>The conventional treatment is planned on two-dimensional images (CT and MRI).</description>
    <arm_group_label>Retrospective group: Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Critieria:&#xD;
&#xD;
        Retrospective group (reference)&#xD;
&#xD;
          -  Patient already operated for the same indication as detailed in the prospective group&#xD;
             inclusion criteria&#xD;
&#xD;
          -  Surgery date within the 6 years before the study activation in the participating&#xD;
             center&#xD;
&#xD;
          -  Adult (18 years old or more) at the time of surgery&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Prospective group (innovation)&#xD;
&#xD;
          -  Primitive malignant pelvic bone tumor or mixt tumor (primary bone sarcoma, soft tissue&#xD;
             sarcoma with bone extension, giant cells tumor of bone and any tumor requiring such a&#xD;
             resection)&#xD;
&#xD;
          -  Indication for a wide monobloc resection according to clinical guidelines of the&#xD;
             pathology (&quot;en bloc&quot; resection of iliac bone including a bone section from&#xD;
             periacetabular Enneking zone 2 to the sacrum zone 4, hip extra-articular resection for&#xD;
             proximal femur tumors and sacral tumor or ilio-sacral tumors that need a vertical&#xD;
             osteotomy or horizontal osteotomy above S2)&#xD;
&#xD;
          -  Ability to fill in Euroqol and TESS questionnaires&#xD;
&#xD;
          -  Adult (18 years old or more)&#xD;
&#xD;
          -  Health insurance holder&#xD;
&#xD;
        Retrospective group (reference)&#xD;
&#xD;
        Patient fulfilling the matching criteria with one patient of the prospective group,&#xD;
        according to the following matching criteria (in order of importance):&#xD;
&#xD;
          1. Tumor location (Enneking zones 1, 2, 1-2, 2-3, 1-2-3, 1-2-4, 1-2-3-4, 1-4, sacrum)&#xD;
&#xD;
          2. Tumor type (chondrosarcoma, osteosarcoma, Ewing, chordoma, other tumor type)&#xD;
&#xD;
          3. Surgery center&#xD;
&#xD;
          4. Tumor size (as close as possible between both patients)&#xD;
&#xD;
          5. Response to chemotherapy (good, bad, not applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prospective group (innovation)&#xD;
&#xD;
          -  Patient suffering from a local recurrence or a metastasis at recruitment time&#xD;
&#xD;
          -  Absence of informed consent&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Minors&#xD;
&#xD;
          -  Adults under guardianship or trusteeship&#xD;
&#xD;
        Retrospective group (reference)&#xD;
&#xD;
          -  Patient not fulfilling the protocol matching criteria&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Gouin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon CRCM Les Massues</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille University Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy Centre Chirurgical Emile Gallé</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Hospital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Hospital Kremlin-Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvis</keyword>
  <keyword>Surgical resection</keyword>
  <keyword>Patient specific instrument</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

